Dr. Scott A. May joins Asymchem's Board of Scientific Advisors

TIANJIN, China, March 13, 2019 /PRNewswire/ -- Asymchem, a leading CDMO of Intermediates and API's for the pharmaceutical industry, today announced that Dr. Scott A. May has joined the Asymchem Board of Scientific Advisors (BSA). Dr. May joins Professors Barry Sharpless, Phil Baran, Stephen Buchwald and others currently on the advisory board.

Scott A. May received his Ph.D. in Chemistry from Indiana University at Bloomington in 1998. In that same year, Dr. May joined the Process Research group at Eli Lilly as a Senior Organic Chemist, and is currently a Research Fellow in the Small Molecule Design and Development group.

Dr. May in his career has been a long-standing advocate of new technology applications, and in particular played a leading role in developing continuous flow processes suitable for scaleup and manufacture.

The BSA was established in June 2013 and consists of 11 academic and industry technical leaders to provide valuable advice on research targets as well up-to-date technologies with potential applications into the CDMO space. Collaborative research opportunities have continued to yield publications in JOC, JACS, OPRD, Science and others.

About Asymchem

Asymchem is a full-service CMC CDMO of API's for the global pharmaceutical industry, providing compliant and sustainable manufacturing solutions worldwide over the lifecycle of a drug. Capabilities include dedicated HPAPI, in-house enzyme evolution and fermentation for biotransformations, end-to-end continuous flow development and application, hydrogenation, cryogenic capabilities, dedicated carbapenem manufacture, and others. Founded in 1997, Asymchem employs 3820 personnel within China over 6 manufacturing sites. The company has been USFDA, TGA, CFDA and MFDS inspected.

SOURCE Asymchem